However, the full PPARγagonists including pioglitazone and rosiglitazone significantly suppressed cell growth in Umuc-3 and 5637 cells (Fig. 2a and b), suggesting PPARγ activation suppresses proliferation of bladder cancer cells in vitro. This evidence concerns the gene PPARG and urinary bladder cancer.